Markets:

Overview

News

Currencies

International

Treasuries

Azenta, Inc. - Common Stock (NQ:AZTA)

39.14 +2.00 (+5.39%)

Delayed Quote Updated: 4:00 PM EST, Nov 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Azenta, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

1 High-Flying Stock with Impressive Fundamentals and 2 We Find Risky

January 01, 2026

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated...

Via StockStory

Azenta (AZTA): Buy, Sell, or Hold Post Q3 Earnings?

December 28, 2025

Azenta trades at $34.56 and has moved in lockstep with the market. Its shares have returned 12.3% over the last six months while the S&P 500 has gained 11.7%.

Via StockStory

Topics Economy Stocks

3 Overrated Stocks We Steer Clear Of

December 18, 2025

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or...

Via StockStory

Corporate Maneuvers: Buybacks Signal Confidence, Insider Trades Spark Scrutiny

December 10, 2025

In a dynamic period for the financial markets, several public companies are making headlines with significant corporate actions. Azenta Inc. (NASDAQ: AZTA) and Fabasoft AG (XTRA: FSY) have recently...

Via MarketMinute

Topics Law Enforcement Regulatory Compliance

Why a $5 Million Bet on Azenta Could Pay Off After a 70% Stock Slide ↗

December 08, 2025

A major earnings reset and fresh fund interest could mark a turning point for this formerly high-flying life-sciences stock.

Via The Motley Fool

Topics Regulatory Compliance

3 Healthcare Stocks We’re Skeptical Of

December 02, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand,...

Via StockStory

Topics Stocks

Q3 Rundown: Azenta (NASDAQ:AZTA) Vs Other Drug Development Inputs & Services Stocks

November 27, 2025

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Azenta (NASDAQ:AZTA) and its peers.

Via StockStory

Why Azenta (AZTA) Stock Is Trading Up Today

November 24, 2025

Shares of life sciences company Azenta (NASDAQ:AZTA) jumped 4.2% in the afternoon session after a report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies.

Via StockStory

Topics Artificial Intelligence Supply Chain

AZTA Q3 Deep Dive: Operational Discipline and Product Strength Support Margin Expansion

November 22, 2025

Life sciences company Azenta (NASDAQ:AZTA) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 5.5% year on year to $159.2 million. Its non-GAAP profit of $0.19 per...

Via StockStory

Why Azenta (AZTA) Stock Is Up Today

November 21, 2025

Shares of life sciences company Azenta (NASDAQ:AZTA) jumped 14.9% in the afternoon session after it reported third-quarter 2025 results that featured better-than-expected revenue and profitability.

Via StockStory

Topics Artificial Intelligence Supply Chain

Which stocks are gapping on Friday? ↗

November 21, 2025

Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

Azenta Inc (NASDAQ:AZTA) Reports Q4 2025 Earnings Beat and Positive Market Reaction ↗

November 21, 2025

Azenta (AZTA) reports Q4 FY2025 results, beating EPS estimates with $0.21 and slightly missing on revenue. The stock rose on the positive earnings news.

Via Chartmill

Topics Earnings

Azenta (NASDAQ:AZTA) Surprises With Q3 CY2025 Sales

November 21, 2025

Life sciences company Azenta (NASDAQ:AZTA) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 5.5% year on year to $159.2 million. Its non-GAAP profit of $0.19 per...

Via StockStory

Earnings Outlook For Azenta ↗

November 20, 2025

Via Benzinga

Azenta (AZTA) Reports Q3: Everything You Need To Know Ahead Of Earnings

November 19, 2025

Life sciences company Azenta (NASDAQ:AZTA) will be reporting results this Friday before the bell. Here’s what to look for.

Via StockStory

3 Unprofitable Stocks We’re Skeptical Of

November 17, 2025

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

Via StockStory

1 Cash-Producing Stock to Consider Right Now and 2 We Avoid

November 16, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

1 Stock Under $50 for Long-Term Investors and 2 We Turn Down

November 13, 2025

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...

Via StockStory

1 High-Flying Stock with Promising Prospects and 2 That Underwhelm

November 11, 2025

Via StockStory

3 Russell 2000 Stocks We Think Twice About

October 31, 2025

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these...

Via StockStory

This Coinbase Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday ↗

October 30, 2025

Via Benzinga

3 Healthcare Stocks We Keep Off Our Radar

October 13, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the...

Via StockStory

Topics Economy Stocks

LifeStance Health Group, Azenta, PacBio, GE HealthCare, and ICU Medical Shares Are Falling, What You Need To Know

October 10, 2025

A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.

Via StockStory

Topics Economy Government World Trade

3 Stocks Under $50 We’re Skeptical Of

September 08, 2025

Via StockStory

Topics Supply Chain

Spotting Winners: Azenta (NASDAQ:AZTA) And Drug Development Inputs & Services Stocks In Q2

August 25, 2025

Let’s dig into the relative performance of Azenta (NASDAQ:AZTA) and its peers as we unravel the now-completed Q2 drug development inputs & services earnings season.

Via StockStory

Repligen, Revvity, Avantor, Fortrea, and Azenta Shares Skyrocket, What You Need To Know

August 22, 2025

A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested...

Via StockStory

Topics Economy

3 Unprofitable Stocks We Steer Clear Of

August 19, 2025

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital...

Via StockStory

Azenta, LifeStance Health Group, BioMarin Pharmaceutical, AMN Healthcare Services, and ANI Pharmaceuticals Stocks Trade Up, What You Need To Know

August 13, 2025

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer...

Via StockStory

Topics Earnings Economy

AZTA Q2 Deep Dive: Product Mix Shifts and Cost Controls Define Flat Quarter

August 13, 2025

Life sciences company Azenta (NASDAQ:AZTA) fell short of the market’s revenue expectations in Q2 CY2025, with sales flat year on year at $143.9 million. Its non-GAAP profit of $0.14 per share was in...

Via StockStory

Topics Economy

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 12, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.